Intraperitoneal chemotherapy for women with epithelial ovarian cancer.
In 2006, i.p. chemotherapy re-emerged as a controversial topic in debates about the optimal treatment for women with advanced epithelial ovarian cancer. In this paper, we address the rationale behind i.p. chemotherapy, the data supporting its use, the selection of appropriate patients for i.p. chemotherapy, how best to avoid and manage the toxicities observed with i.p. chemotherapy, and directions for future research.
Trimble
Edward L
EL
Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, Suite 7025, MSC 7436, Bethesda, Maryland 20892-7436, USA. trimblet@ctep.nci.nih.gov
Thompson
Sharon
S
Christian
Michaele C
MC
Minasian
Lori
L
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral / Q000009:adverse effects; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000523:psychology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000523:psychology; D018579:Patient Selection; D011788:Quality of Life; D016896:Treatment Outcome
D000970:Antineoplastic Agents